Nektar Therapeutics
NKTR
30.20
-2.34
-7.19%
Nektar Therapeutics
US · NKTR
#3017 by market cap
Listed 1970
30.20
-2.34
-7.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price TargetMT Newswires · 2026/10/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC)TipRanks · 2026/10/12
-
Rating change
Leerink Partners Initiates Coverage On Nektar Therapeutics With Outperform Rating, Announces Price Target of $130Benzinga · 2026/10/12
-
Rating change
UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53Market Newswire · 2026/10/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)TipRanks · 2026/10/12
-
Rating change
Nektar Therapeutics Initiated at Outperform by Leerink PartnersDow Jones · 2026/10/12
-
Rating change
Nektar Therapeutics Price Target Announced at $53.00/Share by UBSDow Jones · 2026/10/12
-
Nektar Therapeutics Q3 Loss Narrows, Revenue FallsMT Newswires · 2026/11/13
-
Rating change
UBS Maintains Nektar Therapeutics(NKTR.US) With Hold Rating, Maintains Target Price $53Market Newswire · 2026/10/12
-
Company notice
Nektar Therapeutics | 8-K: Nektar Therapeutics Announces Third Quarter 2026 Financial ResultsSEC · 2026/11/13
-
Company notice
Nektar Therapeutics | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Company notice
Nektar Therapeutics | 10-Q: Quarterly reportSEC · 2026/11/14
-
Rating change
Nektar Therapeutics Initiated at Neutral by UBSDow Jones · 2026/10/12
-
Company notice
Nektar Therapeutics | 8-K: Current reportSEC · 2026/11/13
-
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192Market Newswire · 2026/11/13
-
Wedbush Cuts Price Target on Nektar Therapeutics to $40 From $50, Keeps Neutral RatingMT Newswires · 2026/11/13
-
Rating change
Nektar Therapeutics Price Target Announced at $130.00/Share by Leerink PartnersDow Jones · 2026/10/12
-
Wedbush Maintains Nektar Therapeutics(NKTR.US) With Hold Rating, Cuts Target Price to $40Market Newswire · 2026/11/13
-
Company notice
Nektar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC · 2026/10/21
-
Rating change
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price TargetBenzinga · 2026/10/10
-
Company notice
Nektar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GREER R SCOTTSEC · 2026/9/26
-
Rating change
Nektar Therapeutics Initiated at Market Perform by Raymond JamesDow Jones · 2026/10/9
-
Company notice
Nektar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director WHITFIELD ROY ASEC · 2026/9/26
-
Rating change
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIGDow Jones · 2026/10/10
-
Company notice
Nektar Therapeutics | 8-K: Current reportSEC · 2026/10/1
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.
Nektar Therapeutics discussion 0 comments